EXPERT REVIEWS

Chronic Lyme disease: the controversies and the science

Paul M Lantos

Departments of Internal Medicine and Pediatrics, Division of Pediatric Infectious Diseases, Hospital Medicine Program, Duke University Medical Center, DUMC 100800, Durham, NC 27710, USA
Tel.: +1 919 681 8263
paul.lantos@duke.edu

The diagnosis of chronic Lyme disease has been embroiled in controversy for many years. This is exacerbated by the lack of a clinical or microbiologic definition, and the commonality of chronic symptoms in the general population. An accumulating body of evidence suggests that Lyme disease is the appropriate diagnosis for only a minority of patients in whom it is suspected. In prospective studies of Lyme disease, very few patients go on to have a chronic syndrome dominated by subjective complaints. There is no systematic evidence that *Borrelia burgdorferi*, the etiology of Lyme disease, can be identified in patients with chronic symptoms following treated Lyme disease. Multiple prospective trials have revealed that prolonged courses of antibiotics neither prevent nor alleviate such post-Lyme syndromes. Extended courses of intravenous antibiotics have resulted in severe adverse events, which in light of their lack of efficacy, make them contraindicated.

Each year, tens of thousands of North Americans and Europeans become infected with *Borrelia burgdorferi* sensu lato, the group of related tick-borne spirochetes that cause Lyme disease (Box 1). It is widely assumed that this disease is under-reported, and the actual incidence may approach the hundreds of thousands. Its variety of manifestations continues to pose a challenge to clinicians. As many as 80–90% of patients present with the characteristic erythema migrans rash of early Lyme disease, but if unrecognized and untreated, the organism can disseminate to skin, the heart, the central or peripheral nervous system, and joints. The resultant disease manifestations are usually recognizable based on objective clinical findings, such as aseptic meningitis, nerve palsies, cardiac conduction delays and frank arthritis, and have been definitively attributed to *B. burgdorferi* based on culture nucleic acid detection, or seroreactivity.

It is well-established that some patients experience prolonged somatic or neurocognitive symptoms during convalescence from Lyme disease, and a subset suffer significant functional impairment [1–8]. Whether this phenomenon occurs frequently or rarely, and whether it is caused by persistent infection with *B. burgdorferi*, lie at the heart of the often acrimonious controversy over what has been termed 'chronic Lyme disease'. This controversy primarily exists in the public

dialogue, as the concept of chronic Lyme disease is not widely accepted within the scientific or clinical community. At least 19 independent societies representing the USA and numerous European countries have produced remarkably similar clinical practice guidelines for Lyme disease, discouraging the diagnosis of chronic Lyme disease and recommending against treating patients with prolonged or repeated antibiotic courses [9–27,201]. These recommendations are also shared by national public health agencies throughout the Lyme-endemic world. A small minority of physicians accounts for most diagnoses of chronic Lyme disease: one study found that only six of 285 (2.1%) randomly surveyed physicians in Connecticut, USA, gave patients this diagnosis [28]. Still fewer depart from published guidelines by prescribing extended courses of antibiotics [29].

Does chronic Lyme disease exist?

Most patients who are diagnosed with chronic Lyme disease have prolonged somatic and/or neurocognitive symptoms, such as fatigue, arthralgias or memory impairment, but usually lack the objective findings classically associated with Lyme disease. The term 'chronic Lyme disease' implicitly suggests that these symptoms are caused by infection with *B. burgdorferi*, and it is often argued that infection

Borrelia burgdorferi sensu lato refers to a complex of 18 related genospecies. Of these, *B. burgdorferi* sensu stricto, *B. garinii* and *B. afzelii* are responsible for Lyme disease in Europe. *B. burgdorferi* sensu stricto is the sole agent of Lyme disease in North America. Other genospecies within the complex may have medical importance, but this is currently investigational. As the clinical, microbiologic and taxonomic distinctions within this group are beyond the scope of this article, the designation *B. burgdorferi* is used here for brevity in place of *B. burgdorferi* sensu lato [125].

with this organism may become persistent despite antimicrobial therapy. These assumptions, however, have not translated to any accepted clinical, pathologic or microbiologic definition of the term. One clinical practice guideline devoted to the management of chronic Lyme disease included a provisional definition so broad that Lyme disease could not be differentiated from the myriad other medical conditions (**Box 2**) [30]. Without a definition, the term lacks meaning and it becomes fruitless to debate about whether or not 'chronic Lyme disease' exists as such.

Unable to precisely say what chronic Lyme disease is, we must next examine the features of patients referred for Lyme disease to discern whether there emerges a subset who have verifiable Lyme disease, and who appear to have chronic, treatment-refractory infection. In seven studies conducted in endemic areas, comprising a total of 1902 patients referred for suspected Lyme disease, only 7–31% had active Lyme disease and 5–20% had previous Lyme disease [31–37]. Among the remainder, 50–88% had no evidence of ever having had Lyme disease (**Figure 1**). Most of these patients had either an alternative medical diagnosis or a functional somatic syndrome such as chronic fatigue syndrome or fibromyalgia. A substantial number were diagnosed with Lyme disease based on an inability to make an alternative diagnosis – referred to in one paper as 'diagnosis of Lyme disease by exclusion' [36]. Primary psychiatric diagnoses, psychiatric comorbidity and psychological traits such as catastrophization and negative affect are also common [32,34]. Many had symptoms of long duration and had received multiple courses of antibiotics directed at Lyme disease. Similar observations were made in Vancouver, British Columbia, where Lyme disease is very rare; of 65 patients referred for Lyme disease, 61 had either an alternative medical diagnosis or a functional somatic syndrome, and nine had a primary psychiatric diagnosis [38].

These studies underscore the degree of concern about Lyme disease in clinical practice, but even in the most highly endemic areas, less than a third of referred patients prove to have the disease in the end. The remainder appears to divide into at least three broad categories: those with alternative medical diagnoses, those with functional somatic syndromes, and a minority who have persistent symptoms that follow treatment for Lyme disease. This is true, notwithstanding the results of diagnostic testing: while a negative test may help exclude Lyme disease in patients with a low pretest probability, a positive test does not necessarily confirm the diagnosis in this scenario [39]. The positive predictive value of Lyme serodiagnostics is poor in patients with only nonspecific symptoms. Patients may coincidentally have positive Lyme serology for a variety of reasons, including asymptomatic seroconversion, generation of cross-reactive antibodies in other infectious or inflammatory diseases, or a previous treated episode of Lyme disease, and the prevalence of asymptomatic seropositivity may match or exceed the cumulative incidence of confirmed disease [31,35,36,39–46].

The differential diagnosis of chronic Lyme disease

Many patients referred for Lyme disease are often found to have a rheumatologic or neurologic diagnosis. Osteoarthritis, rheumatoid arthritis (RA), degenerative diseases of the spine and spondyloarthropathies are the most common rheumatologic conditions identified in these patients [32,33,47]. Some patients are found to have neurologic diseases, including multiple sclerosis (MS), demyelinating diseases, amyotrophic lateral sclerosis (ALS) and neuropathies [33]. Some authors and patient advocates have proposed that in actuality Lyme disease is the true or underlying etiology in many patients who have received these alternative medical diagnoses [30,48–50]. This seems to be quite unlikely given that many of these diseases result in rather specific medical syndromes that do not concentrate in areas with heavy *B. burgdorferi* transmission, such as the Northeastern and upper Midwestern USA [51]. Even if one were to stipulate that very atypical presentations of Lyme disease (i.e., resembling ALS) went unrecognized by public health authorities, and that surveillance numbers are skewed by too narrow a case definition, one would still expect to see clustering in areas where Lyme transmission is heaviest. This is not the case. MS, for instance, occurs at substantial rates in areas with little or no endemic transmission of *B. burgdorferi*, such as Washington state, USA, Northern Canada, Iceland and arctic Norway [52]. Similarly, the medical literature fails to yield evidence that ALS, Parkinson's disease, RA or spondyloarthropathies cluster in areas with the highest incidence rates of Lyme disease. While there can certainly be clinical overlap between Lyme disease and other clinical entities, objective findings and studies will generally allow the clinician to differentiate between them [53–55].

Syndromes such as fibromyalgia and chronic fatigue syndrome, as well as less specific chronic syndromes (variably called

For the purpose of the ILADS guidelines, 'chronic Lyme disease' is inclusive of persistent symptomatologies including fatigue, cognitive dysfunction, headaches, sleep disturbance and other neurologic features, such as demyelinating disease, peripheral neuropathy and sometimes motor neurone disease, neuropsychiatric presentations, cardiac presentations including electrical conduction delays and dilated cardiomyopathy and musculoskeletal problems.

ILADS: International Lyme and Associated Diseases Society.
Taken from [30].

'medically unexplained systems', 'functional pain syndromes' or 'chronic multisystem illness') account for most of the remaining patients who are referred for chronic Lyme disease. Unlike Lyme disease, these frustrating conditions generally lack objective clinical or histopathological abnormalities, and are dominated by subjective complaints and functional impairment [56–58]. Neither fibromyalgia nor chronic fatigue syndrome is known to geographically cluster with *B. burgdorferi* transmission. Fibromyalgia has been found to temporally follow Lyme disease in some cases: in a prospective study of 287 patients treated for confirmed Lyme disease, 22 (8%) went on to develop fibromyalgia within 5 months of treatment [59]. Additional antibiotics were not beneficial. It must be noted that fibromyalgia and chronic fatigue can temporally follow a variety of infections, including, but not limited to, infection with *B. burgdorferi* [56,60].

Figure 1. Categorization of persons referred for Lyme disease in endemic areas.
Alternative diagnoses are categorized differently in the cited references, but include definite alternative medical diagnoses, chronic functional syndromes (e.g., fibromyalgia), symptomatic persons with no adequate explanation and asymptomatic persons referred because of abnormal test results
Data taken from [31–37].

Post-Lyme disease syndromes

The designation 'post-Lyme disease syndromes' has been proposed to describe patients who experience prolonged subjective symptoms following Lyme disease [26]. It is more properly thought of as a means of categorizing this patient cohort, rather than describing a clinical diagnosis. The case definition of post-Lyme disease syndromes differs from 'chronic Lyme disease' chiefly in its requirements that patients have: unequivocal documentation of appropriately-treated Lyme disease; and persistent subjective symptoms that cannot be explained by other medical illnesses (Box 3). The definition contains abundant exclusion criteria. In particular, this concept must be distinguished from treatment failure – for instance, persistence, relapse or development of objective signs of disease as occasionally happens in the treatment of Lyme disease.

The most common complaints among patients with post-Lyme disease syndromes are arthralgias, myalgias, headache, neck and backache, fatigue, irritability and cognitive dysfunction (particularly perceived difficulty with memory and concentration). While some patients have objective cognitive deficits, many who subjectively complain of cognitive dysfunction are found to be normal when formally tested [3,7,61–65]. The attribution of these symptoms to Lyme disease is complicated by their extraordinarily high background rate in the population at large, and in fact their frequency might be no greater than that expected by chance alone. Up to 20% of the general population experiences chronic fatigue [66,67]. In one survey using three different assessment instruments, 3.75–12.1% of the general population suffered severe pain and 36.4–45.1% moderate pain; in fact, only 42.5–59.1% of the general population was pain-free [68]. In a separate study 11.2% of respondents suffered chronic, widespread pain [69]. A quarter to a third of the general population

describe chronic cognitive dysfunction [68]. These symptoms often coincide with anxiety or depression, which in turn affected 25% of subjects in this study.

The rarity of post-Lyme disease syndromes is exemplified by the great difficulty three investigative teams had in recruiting subjects for clinical trials investigating this condition [2,4,5]. Of 5846 patients screened over several years, only 222 (3.8%) could ultimately be randomized, a striking finding given that most of the 20,000 annual cases of Lyme disease occur in the region where these studies are conducted. The dominant reason for this is that very few of the screened patients had documentation of prior Lyme disease. This suggests that the attribution of chronic symptoms to Lyme disease is grossly out of proportion to its actual occurrence.

Interestingly, in most longitudinal studies of Lyme disease, the prevalence of chronic post-treatment symptoms is no higher than their prevalence in the population at large. From the many trials that distinguish treatment failures from syndromes with only subjective complaints, the following themes emerge: residual symptoms are common in the first weeks after therapy in persons who have no objective evidence of treatment failure; symptoms persisting many months or years are uncommon; and disabling symptoms lasting months or years are extremely rare. In ten prospective studies of erythema migrans and early disseminated Lyme disease, fewer than 10% of subjects described persistent symptoms such as myalgias and fatigue after 9 or more months (range 0–23%), and the prevalence of severe symptoms was 0–2.8% [65,70–78]. One recently published trial found that after 12 months, patients treated for erythema migrans were no more likely to have subjective symptoms than an uninfected control group [70].

Box 3. Proposed definition of post-Lyme disease syndromes.

Inclusion criteria

- An adult or child with a documented episode of early or late Lyme disease fulfilling the case definition of the CDC. If based on erythema migrans, the diagnosis must be made and documented by an experienced healthcare practitioner.
- After treatment of the episode of Lyme disease with a generally accepted treatment regimen, there is resolution or stabilization of the objective manifestation(s) of Lyme disease.
- Onset of any of the following subjective symptoms within 6 months of the diagnosis of Lyme disease and persistence of continuous or relapsing symptoms for at least a 6-month period after completion of antibiotic therapy:
    – Fatigue
    – Widespread musculoskeletal pain
    – Complaints of cognitive difficulties
- Subjective symptoms are of such severity that, when present, they result in substantial reduction in previous levels of occupational, educational, social or personal activities.

Exclusion criteria

- An active, untreated, well-documented coinfection, such as babesiosis.
- The presence of objective abnormalities on physical examination or on neuropsychologic testing that may explain the patient's complaints. For example, a patient with antibiotic refractory Lyme arthritis would be excluded. A patient with late neuroborreliosis associated with encephalopathy, who has recurrent or refractory objective cognitive dysfunction, would be excluded.
- A diagnosis of fibromyalgia or chronic fatigue syndrome before the onset of Lyme disease.
- A prolonged history of undiagnosed or unexplained somatic complaints, such as musculoskeletal pains or fatigue, before the onset of Lyme disease.
- A diagnosis of an underlying disease or condition that might explain the patient's symptoms (e.g., morbid obesity, with a BMI [calculated as weight in kilograms divided by the square of height in meters] ≥45; sleep apnea and narcolepsy; side effects of medications; autoimmune diseases; uncontrolled cardiopulmonary or endocrine disorders; malignant conditions within 2 years, except for uncomplicated skin cancer; known current liver disease; any past or current diagnosis of a major depressive disorder with psychotic or melancholic features; bipolar affective disorders; schizophrenia of any subtype; delusional disorders of any subtype; dementias of any subtype; anorexia nervosa or bulimia nervosa; and active drug abuse or alcoholism at present or within 2 years).
- Laboratory or imaging abnormalities that might suggest an undiagnosed process distinct from post-Lyme disease syndrome, such as a highly elevated erythrocyte sedimentation rate (150 mm/h); abnormal thyroid function; a hematologic abnormality; abnormal levels of serum albumin, total protein, globulin, calcium, phosphorus, glucose, urea nitrogen, electrolytes or creatinine; significant abnormalities on urine analysis; elevated liver enzyme levels; or a test result suggestive of the presence of a collagen vascular disease.
- Although testing by either culture or PCR for evidence of *Borrelia burgdorferi* infection is not required, should such testing be done by reliable methods, a positive result would be an exclusion.

Taken from [26].

Objective clinical residua are well known to follow antibiotic therapy for confirmed Lyme disease. Facial nerve palsy and other objective neurologic defects may persist for months in patients treated for acute neurologic Lyme disease, exceeding 20% in some studies. Less than 1%, however, go on to have chronic fatigue, nonspecific pain or other symptom complexes compatible with the post-Lyme disease syndromes [79–87]. Approximately 10% of patients treated for Lyme arthritis go on to have a unique syndrome termed 'antibiotic-refractory Lyme arthritis', a persistent sterile synovitis that can last for months to years. This condition, based on factors including antibiotic refractoriness and strong association with *HLA-DRB1*0401*, appears to be a postinfectious autoimmune phenomenon [88]. Based on lack of evidence of viable *B. burgdorferi* and unresponsiveness to antibiotics, neither of these phenomena is thought to be an active infection.

Gradual convalescence is observed after many systemic infections. For example, following bacterial pneumonia nonspecific symptoms that impair quality of life can greatly exceed the duration of respiratory symptoms, sometimes by months [89]. It seems unlikely that post-Lyme symptoms are any more common than similar symptoms after other infections.

Biological plausibility

No adequately controlled, hypothesis-driven study using a repeatable method has demonstrated that viable *B. burgdorferi* is found in patients with persistent post-Lyme symptoms any more frequently than in those with favorable outcomes. In three clinical trials, comprising more than 150 subjects with strictly-defined post-Lyme disease symptoms, no patient was found to have positive culture or PCR of cerebrospinal fluid [2,4]. However, these studies were unique in that they investigated evidence of persistent *B. burgdorferi* infection in a prospectively defined group of chronically ill subjects. Other sources of data include case reports and case-series, which however compelling are inherently incapable of testing a hypothesis. Advocates of chronic Lyme disease contend that our ability to detect the organism is hampered by current technology and an incomplete scientific understanding of *B. burgdorferi*, and that conventional diagnostic testing misses patients with chronic Lyme disease [90,91]. However, this begs the question of on what microbiologic basis we assume that chronic *B. burgdorferi* infection exists at all.

Studies meant to support the etiologic role of *B. burgdorferi* in chronic symptom complexes have, at times, relied on investigational testing methods. This has included the use of novel culture

media, detection of *B. burgdorferi* DNA in urine specimens and enumeration of CD57-positive lymphocytes [92–95]. Subsequent investigations, however, have discredited the reliability of these initial reports and cast doubt more generally on their utility as diagnostic tests [96–99]. Other arguments, meant to illustrate the plausibility that *B. burgdorferi* can persist following antibiotic therapy, have noted the detection of the organism by xeno-diagnosis, culture or PCR [100–104]. However, these reports are at best circumstantial, in that they have only been performed in patients with early Lyme disease, Lyme arthritis and in laboratory animals – never in patients with a putative diagnosis of chronic Lyme disease. Furthermore, the complete eradication of micro-organisms is, only in rare cases, a measure of treatment success; rather, clinical end points are what usually guide anti-infective therapy. Morphologic variants of *B. burgdorferi*, variably known as 'cyst forms', 'spheroplasts' or 'cell wall-deficient forms' have not been isolated from patients with post-Lyme disease [105–109]. Despite their frequent mention as the underlying cause of chronic Lyme disease, their actual role remains purely hypothetical. As these forms have been most often observed in antibiotic-treated specimens or in *ex vivo* conditions, it is possible that they represent sick or stressed microorganisms. Their virulence has not been established.

Risk factors for post-Lyme disease syndromes

As there is a lack of evidence that post-Lyme disease patients remain infected with *B. burgdorferi*, it is perhaps not surprising that the duration of initial antibiotic therapy does not influence the persistence of subjective symptoms. A prospective trial of therapy for 180 patients with early Lyme disease found that after 30 months, neuropsychologic deficits were equally common among patients treated for 10 versus 20 days [77]. In a retrospective study of 607 patients treated for early Lyme disease, 99 ± 0.2% of patients were well after 2 years of follow-up, regardless of whether they had received less than 10, 11–14 or greater than 14 days of therapy [110]. In a randomized, open-label trial of therapy for late Lyme disease, patients treated for 14 days were no more likely to have severe symptoms than those treated for 28 days – despite the fact that objective treatment failures were significantly more likely in the 14-day arm [111]. Lengthy courses of antibiotics, meant to prevent the development of persistent symptoms, are no more effective than conventional courses. Following 3 weeks of parenteral ceftriaxone, an additional 100 days of oral amoxicillin was no better than placebo at improving cognitive and somatic outcomes [112].

Since the earliest treatment trials of Lyme disease, the factor that has most consistently predicted persistence of symptoms is their severity before initiation of therapy [113–115]. Severe headache, arthritis, arthralgias and fatigue at presentation predicted persistent symptoms in a retrospectively examined cohort of 215 patients [116]. In a prospective treatment trial for early Lyme disease, persistent symptoms at several late follow-up visits (6 months through 5 years) were more common in patients who had more symptoms, higher symptom scores and multiple (versus solitary) erythema migrans lesions [75]. Patients with a longer duration of symptoms may also be at higher risk

of persistent symptoms: a review of 38 subjects who had been previously treated for Lyme disease found that persistent somatic and neuropsychological sequelae were strongly associated with prolonged illness prior to treatment [7].

Extended antibiotics for the treatment of post-Lyme disease syndromes

To date, three research groups have prospectively examined the utility of prolonged antibiotics in treating post-Lyme disease syndromes [2–5]. All trials had strict entrance criteria, requiring that enrollees have firm documentation of prior Lyme disease and receipt of appropriate antibiotic therapy, followed within 6 months by persistent symptoms. The first study, published in 2001 by Klempner *et al.*, reported two parallel trials in which their cohort of 129 study patients was divided into seropositive (n = 78) and seronegative (n = 51) arms [4]. Patients randomized to treatment groups received 30 days of intravenous (iv.) ceftriaxone followed by 60 days of oral doxycycline. Patients randomized to the placebo arm received a placebo iv. infusion for 30 days, followed by an oral placebo for 60 days. The primary outcome of interest was health-related quality of life as assessed by standardized instruments (the Medical Outcomes Study 36-item Short-Form General Health Survey [SF-36] and the Fibromyalgia Impact Questionnaire). These instruments were administered at baseline, then 30, 90 and 180 days. There was no significant difference in any outcome measure between placebo and treatment groups in either the seropositive or seronegative arm. In a separate publication, the same team of investigators reported the performance of this study cohort on a detailed battery of neuropsychological tests, which included measurements of cognitive function, somatic symptoms and mood [3]. Although all patients complained of cognitive dysfunction at baseline (and the primary complaint in more than 70%), objective measures of cognitive function, such as memory and attention, were normal compared with age-referenced normative data. Depression, anxiety and somatic complaints improved in all groups between baseline and day 180, but there was no difference between the treatment and placebo groups.

In a separate trial, Krupp and colleagues evaluated 28 days of parenteral ceftriaxone (n = 28) versus iv. placebo (n = 24) in a cohort of patients with persistent fatigue following treated Lyme disease [5]. The primary outcome measure was score on the Fatigue Severity Scale (FSS-11). Additional outcomes were visual analogue scales (VAS) of fatigue and pain, the SF-36 and the Center for Epidemiologic Studies Depression Scale, and a comprehensive battery of cognitive function. Outcomes were measured at baseline and at 6 months. Baseline fatigue was severe. At follow-up, there was a statistically significant but partial improvement on the FSS-11 in the ceftriaxone arm compared with placebo, with 18/26 (69%) versus 5/22 (23%) showing improvement from baseline. The fatigue VAS, although not statistically significant, corroborated a benefit for the treatment arm (p = 0.08). No measure of mood or cognitive function differed at 6 month follow-up. It was noted that a much higher proportion of patients on ceftriaxone correctly guessed their treatment assignment. Whether this was a failure of masking or rather a placebo effect (i.e., the majority in both groups believed they

were on active therapy), and whether this would have affected the outcome of a subjective measure like fatigue, is difficult to discern. The commonality and nonspecificity of fatigue, and the observation that antibiotics may improve chronic fatigue in noninfectious or other postinfectious illnesses, raise doubts as to whether it was the elimination of *B. burgdorferi* that resulted in this outcome [117–119].

The efficacy of more prolonged parenteral therapy was investigated by Fallon *et al.* [2]. In this cohort, 23 patients were randomized to receive iv. ceftriaxone and 14 patients to receive iv. placebo for 10 weeks, followed by 14 weeks of observation off of therapy. Six domains of cognitive function were tested and compiled to produce a composite 'cognitive index' score. The primary outcome of interest was cognitive index compared with baseline and between groups at week 24. An interim evaluation at week 12 demonstrated significant improvement over baseline in the ceftriaxone group ($p < 0.01$), whereas this was not the case for the placebo group. A between-group comparison approached statistical significance ($p = 0.053$) at week 12 also. At week 24, however, these differences had disappeared: both groups had significantly and equally improved over their within-group baseline, and there was no difference between groups ($p = 0.76$). Three ceftriaxone and two placebo patients (13.5% of the randomized subjects) withdrew from the trial due to adverse events related to either the iv. catheter or the drug, leaving only 20 drug and 12 placebo patients available for statistical analysis. An additional four ceftriaxone patients remained in the study despite adverse events that truncated their therapy. The patients who dropped out were not analyzed by intention to treat, which, given the small sample size in this trial, might have affected the published statistics.

Adverse events, in fact, abounded in these studies, particularly catheter-associated venous thromboembolism, catheter-associated septicemia, allergic reactions and ceftriaxone-induced gallbladder toxicity. In the Klempner *et al.* trial, one patient on ceftriaxone suffered a pulmonary embolism and one experienced a syndrome of fever, anemia and gastrointestinal bleeding that was thought to be an allergic phenomenon [3,4]. In the Krupp *et al.* trial, three patients on iv. placebo developed line sepsis, and one patient on ceftriaxone had an anaphylactic reaction [5]. In the Fallon *et al.* trial, six patients on ceftriaxone had adverse events: two venous thromboembolic events, three allergic reactions and one case of ceftriaxone-induced cholecystitis (treated with cholecystectomy), in addition to a placebo patient who developed line sepsis [2].

Other studies reiterate the frequency of adverse events in persons with prolonged exposure to intravenous catheters and antibiotics. In an observational study by Stricker *et al.,* there were 19 potentially life-threatening adverse events among 200 patients on long term iv. antibiotics for the treatment of chronic Lyme disease [120]. These included four cases of venous thrombosis, six cases of suspected line sepsis, seven patients with allergic reactions and two patients who developed ceftriaxone-induced gallbladder disease (both cases managed with cholecystectomy). The mean duration of antibiotic therapy in this cohort was 118 days, and the adverse events reported occurred after a mean of 81 days from initiation of therapy. This rate of severe adverse events – nearly 10% of subjects – is exceeded only by the Fallon *et al.* trial (24%) [2]. The duration

of exposure to central venous access devices and iv. drug therapy in these two studies differentiate them from the Klempner *et al.* and Krupp *et al.* studies, and this almost certainly explains the high rate of adverse events. While no deaths occurred in these studies, there have indeed been documented fatalities and near-fatalities due to prolonged iv. antibiotic therapy for putative Lyme disease [121–123].

While controlled data demonstrate that prolonged antibiotics are unlikely to be helpful, the critical judgment is whether they are worth the risk. The prospective clinical trials, which were designed to address questions of efficacy, speak much more clearly to the risk of toxicity. Without a doubt there is a significant risk to patients who are on months of iv. antibiotics. Given the risks, it is impossible to argue that prolonged iv. antibiotics are ethically justified for patients with post-Lyme disease syndromes. These same risks naturally apply to other situations in medicine in which prolonged antibiotic therapy is required. The risk/benefit calculus is quite different, though, for infections such as osteomyelitis or endocarditis when the therapy is demonstrably limb-saving or life saving.

A clinical approach to patients seeking treatment for chronic Lyme disease

Patients who seek subspecialty care for chronic Lyme disease are medically heterogeneous and have diverse backgrounds, perspectives and medical literacy. Even the motivation for subspecialty referral can vary. In many cases the referral is driven by concern on the part of the patient or a relative. Some patients come with strongly held expectations based on independent research or on the experiences of their friends and family. Some patients have received other diagnoses that they initially find difficult to accept, and maintain the hope that therapy for Lyme disease will help. In other cases it is a concerned referring physician who makes the referral.

Fundamentally, however, what unites the majority of these patients is their suffering, regardless of whether or not Lyme disease is ultimately to blame. Many have physical impairments, have missed extensive amounts of work or school, their social and family lives have suffered, and they are unable to achieve their personal goals. To make matters worse, some have grown frustrated or cynical with the medical profession because of ineffective treatments, unsatisfying explanations and fruitless testing. A commonly expressed perception is that physicians become impatient or dismissive once it becomes apparent that a patient's symptoms are medically inexplicable. In other words, a dominant feeling is that the suffering of these patients is not effectively heard or validated.

Several strategies can make these challenging encounters both rewarding and beneficial. First, in the absence of a definition, it is impossible to know exactly what is meant by 'chronic Lyme disease' when a patient presents for its evaluation. For this reason, it is usually unproductive to make the visit a referendum on the subject. Rather, as with any consultation, it is best to concentrate on the patient's specific clinical story with the goal of making the best diagnosis *de novo*. This often means that nothing important can be taken for granted, including diagnoses the patient has

previously received. The clinical evaluation must begin 'from scratch', starting with the chief complaint and history of present illness, and verification of important test results by reviewing a patient's medical record. Communication, both verbal and non-verbal, matters greatly. Eye contact, attention, patience, humility and empathy are critical. Although these visits are often lengthy parts of otherwise busy schedules, it is imperative to avoid the appearance of being too busy, or of having come to a rash judgment about a patient based on preconceptions about the chronic Lyme disease controversy. It hardly requires reiteration that these strategies are useful not just for Lyme disease and other controversies, but nearly all aspects of patient care.

Expert commentary & five-year view

Two ongoing NIH-registered clinical trials may enhance our current understanding of the post-Lyme disease syndromes. In September 2010, a Dutch trial began randomizing patients with post-Lyme disease syndromes to receive 12 weeks of doxycycline, clarithromycin plus hydroxychloroquine, or placebo following an initial course of ceftriaxone [202]. The primary outcome measure will be the SF-36 medical outcomes scale at week 14, as well as repeated assessments that include fatigue and neuropsychologic testing up until week 40. This will be the first prospective, placebo-controlled trial of post-Lyme disease syndromes conducted in Europe. A multisite American study is now investigating the use of xenodiagnosis to detect *B.burgdorferi* in patients with post-Lyme disease syndromes [203]. The investigators are allowing laboratory-raised ticks to feed on subjects with a variety of manifestations of Lyme disease in order to identify human-to-tick transmission. The study will include subjects with confirmed pretreatment infection as positive controls and healthy uninfected volunteers as negative controls.

Two important research gaps are: what pathophysiologic mechanisms underlie chronic pain and chronic fatigue?; and what nonantibiotic modalities are helpful for patients with post-Lyme disease syndromes? The former is an area of tremendous general interest given the ubiquity of such symptoms in the general population. The latter is a puzzlingly understudied field, but it has promise to improve the lives of many who suffer chronic symptoms attributed to Lyme disease – whether or not a history of Lyme disease is ultimately to blame. Furthermore, these may be far safer than prolonged antibiotics and indwelling vascular access devices. A variety of such interventions have proved useful in patients with functional pain syndromes, chronic fatigue syndrome and other debilitating chronic medical illnesses. These include antidepressants, pregabalin and gabapentin, analgesics, biofeedback and complementary and alternative medicine. To date, the only published study is a small open-label trial that found that gabapentin reduced pain in 9/10 and improved quality of life in 5/10 patients with chronic post-Lyme neuropathic pain [124]. Until the medical community has better explanations and therapies for the millions who suffer unexplained chronic symptoms, some patients looking for answers will still come to blame Lyme disease for their illness. This is likely to remain the case 5 years from now.

Financial & competing interests disclosure

Key issues

- Chronic Lyme disease lacks an accepted clinical definition, and in practice the term has been applied to a wide variety of patients. The majority of patients referred for chronic Lyme disease have no objective evidence of the infection, and most often have an alternative medical diagnosis or a 'functional' syndrome such as fibromyalgia or chronic fatigue syndrome.

- Fatigue, pain and cognitive impairment are the primary complaints among patients who are diagnosed with chronic Lyme disease. However, these symptoms are very common in the general population, and the evidence does not show that they occur any more commonly in patients with a history of Lyme disease.

- A small minority of patients treated for Lyme disease will go on to have prolonged pain, fatigue or cognitive impairment in the absence of objective signs of treatment failure. Still fewer have severe or disabling symptoms.

- There is no controlled evidence that viable *Borrelia burgdorferi* persists in patients with prolonged, subjective symptoms following confirmed Lyme disease.

- The duration of initial antibiotic therapy for Lyme disease does not influence the likelihood of prolonged somatic or cognitive symptoms. On the other hand, the duration and severity of symptoms prior to treatment do predict the likelihood of prolonged symptoms during convalescence.

- To date, four prospective, double-blinded, placebo-controlled trials have investigated the utility of prolonged antibiotics in patients with subjective 'post-Lyme disease syndromes'. With only one exception (fatigue) in one trial, no primary outcome measure favored treatment over placebo.

- Potentially severe adverse events due to antibiotic therapy and intravascular access devices are common in patients being treated for post-Lyme disease syndromes. These events directly correlate with duration of treatment. Thus, because of a lack of benefit and strong evidence of harm, lengthy courses of antibiotics are not justified in patients with post-Lyme disease syndromes.

References

1   Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. *N. Engl. J. Med.* 323(21), 1438–1444 (1990).

2   Fallon BA, Keilp JG, Corbera KM *et al.* A randomized, placebo-controlled trial of repeated iv antibiotic therapy for Lyme encephalopathy. *Neurology* 70(13), 992–1003 (2008).

3   Kaplan RF, Trevino RP, Johnson GM *et al.* Cognitive function in post-treatment Lyme disease: do additional antibiotics help? *Neurology* 60(12), 1916–1922 (2003).

4   Klempner MS, Hu LT, Evans J *et al.* Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. *N. Engl. J. Med.* 345(2), 85–92 (2001).

5   Krupp LB, Hyman LG, Grimson R *et al.* Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. *Neurology* 60(12), 1923–1930 (2003).

6   Steere AC, Levin RE, Molloy PJ *et al.* Treatment of Lyme arthritis. *Arthritis Rheum.* 37(6), 878–888 (1994).

7   Shadick NA, Phillips CB, Logigian EL *et al.* The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. *Ann. Intern. Med.* 121(8), 560–567 (1994).

8   Sigal LH. Persisting complaints attributed to chronic Lyme disease: possible mechanisms and implications for management. *Am. J. Med.* 96(4), 365–374 (1994).

9   Société de pathologie infectieuse de langue française. Lyme borreliose: diagnostic, therapeutic and preventive approaches – long text. *Med. Mal. Infect.* 37(Suppl. 3), S153–S174 (2007).

10   Neuroborreliose. *Leitlinien der Deutschen Gesellschaft für Neurologie.* [Neuroborreliosis: *Guidelines of the German Society for Neurology*] Leitlinien-Register Nr 030/071 (2008) (In German).

11   Läkemedelsbehandling av borreliainfektion – ny rekommendation. [Drug treatment of Lyme disease: New Recommendation]. *Information Från Läkemedelsverket* 4, 12–17 (2009) (In Swedish).

12   Kutane Manifestationen der Lyme Borreliose. *Leitlinien der Deutschen Dermatologischen Gesellschaft, Arbeitsgemeinschaft für Dermatologische Infektiologie* [Cutaneous manifestations of Lyme borreliosis. Guidelines of the German Society of Dermatology, Dermatologic Association for Infectious Diseases]. Leitlinien-Register Nr 013/044 (2009) (In German).

13   (AAP) AAoP. Lyme disease (Lyme Borreliosis, *Borrelia burgdorferi* infection). In: *Red Book: 2009 Report of the Committee on Infectious Diseases. 28th Ed.* Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds). American Academy of Pediatrics, Elk Grove Village, IL, USA, 430–435 (2009).

14   Dessau RB, Bangsborg JM, Jensen TP, Hansen K, Lebech AM, Andersen CO. Laboratory diagnosis of infection caused by *Borrelia burgdorferi*. *Ugeskr. Laeg.* 168(34), 2805–2807 (2006).

15   Evison J, Aebi C, Francioli P *et al.* Diagnostic et traitement de la borréliose de Lyme chez l'adulte et l'enfant: recommandations de la Société suisse d'infectiologie [Diagnosis and treatment of Lyme disease in adults and children: Recommendations of the Swiss Society of Infectious Diseases]. *Revue Médicale Suisse* 2, 919–924 (2006) (In French).

16   Flisiak R, Pancewicz S. Diagnostics and treatment of Lyme borreliosis. Recommendations of Polish Society of Epidemiology and Infectious Diseases. *Przegl Epidemiol.* 62(1), 193–199 (2008).

17   Halperin JJ, Shapiro ED, Logigian E *et al.* Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 69(1), 91–102 (2007).

18   Lantos PM, Charini WA, Medoff G *et al.* Final report of the Lyme disease review panel of the Infectious Diseases Society of America. *Clin. Infect. Dis.* 51(1), 1–5 (2010).

19   Ljostad U, Mygland A. Lyme borreliosis in adults. *Tidsskr. Nor. Laegeforen.* 128(10), 1175–1178 (2008).

20   Mygland A, Ljostad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. *Eur. J. Neurol.* 17(1), 8–16, e11–e14 (2010).

21   O'Connell S. Recommendations for the diagnosis and treatment of Lyme borreliosis: guidelines and consensus papers from specialist societies and expert groups in Europe and North America. Presented at: *Federation of Infections Societies (FIS) "Infection 2009" conference.* Birmingham, UK, 11–13 November, 2009.

22   Oksi J. Diagnostics and treatment of Lyme borreliosis. *Duodecim* 116(6), 605–612 (2000).

23   Speelman P, de Jongh BM, Wolfs TF, Wittenberg J. Guideline 'Lyme borreliosis'. *Ned. Tijdschr. Geneeskd.* 148(14), 659–663 (2004).

24   Strle F. Principles of the diagnosis and antibiotic treatment of Lyme borreliosis. *Wien. Klin. Wochenschr.* 111(22–23), 911–915 (1999).

25   Vanousova D, Hercogova J. Lyme borreliosis treatment. *Dermatol. Ther.* 21(2), 101–109 (2008).

26   Wormser GP, Dattwyler RJ, Shapiro ED *et al.* The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. *Clin. Infect. Dis.* 43(9), 1089–1134 (2006).

27   Stanek G, O'Connell S, Cimmino M *et al.* European Union Concerted Action on Risk Assessment in Lyme Borreliosis: clinical case definitions for Lyme borreliosis. *Wien. Klin. Wochenschr.* 108(23), 741–747 (1996).

28   Johnson M, Feder HM Jr. Chronic Lyme disease: a survey of Connecticut primary care physicians. *J. Pediatr.* 157(6), 1025–1029. e1–e2 (2010).

29   Murray T, Feder HM Jr. Management of tick bites and early Lyme disease: a survey of Connecticut physicians. *Pediatrics* 108(6), 1367–1370 (2001).

30   Cameron D, Gaito A, Harris N *et al.* Evidence-based guidelines for the management of Lyme disease. *Expert Rev. Anti Infect. Ther.* 2(Suppl. 1), S1–S13 (2004).

31   Reid MC, Schoen RT, Evans J, Rosenberg JC, Horwitz RI. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. *Ann. Intern. Med.* 128(5), 354–362 (1998).

32   Sigal LH. Summary of the first 100 patients seen at a Lyme disease referral center. *Am. J. Med.* 88(6), 577–581 (1990).

33   Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. *JAMA* 269(14), 1812–1816 (1993).

34   Hassett AL, Radvanski DC, Buyske S, Savage SV, Sigal LH. Psychiatric comorbidity and other psychological factors in patients with "chronic Lyme disease". *Am. J. Med.* 122(9), 843–850 (2009).

35 Qureshi MZ, New D, Zulqarni NJ, Nachman S. Overdiagnosis and overtreatment of Lyme disease in children. *Pediatr. Infect. Dis. J.* 21(1), 12–14 (2002).

36 Rose CD, Fawcett PT, Gibney KM, Doughty RA. The overdiagnosis of Lyme disease in children residing in an endemic area. *Clin. Pediatr. (Phila.)* 33(11), 663–668 (1994).

37 Djukic M, Schmidt-Samoa C, Nau R, Von Steinbuchel N, Eiffert H, Schmidt H. The diagnostic spectrum in patients with suspected chronic Lyme neuroborreliosis – the experience from one year of a university hospital's Lyme neuroborreliosis outpatients clinic. *Eur. J. Neurol.* 18(4), 547–555 (2010).

38 Burdge DR, O'Hanlon DP. Experience at a referral center for patients with suspected Lyme disease in an area of nonendemicity: first 65 patients. *Clin. Infect. Dis.* 16(4), 558–560 (1993).

39 Tugwell P, Dennis DT, Weinstein A *et al.* Laboratory evaluation in the diagnosis of Lyme disease. *Ann. Intern. Med.* 127(12), 1109–1123 (1997).

40 Smith HV, Gray JS, McKenzie G. A Lyme borreliosis human serosurvey of asymptomatic adults in Ireland. *Zentralbl. Bakteriol.* 275(3), 382–389 (1991).

41 Zhioua E, Gern L, Aeschlimann A, Sauvain MJ, Van der Linden S, Fahrer H. Longitudinal study of Lyme borreliosis in a high risk population in Switzerland. *Parasite* 5(4), 383–386 (1998).

42 Steere AC, Sikand VK, Meurice F *et al.* Vaccination against Lyme disease with recombinant *Borrelia burgdorferi* outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. *N. Engl. J. Med.* 339(4), 209–215 (1998).

43 Steere AC, Sikand VK, Schoen RT, Nowakowski J. Asymptomatic infection with *Borrelia burgdorferi*. *Clin. Infect. Dis.* 37(4), 528–532 (2003).

44 Fahrer H, van der Linden SM, Sauvain MJ, Gern L, Zhioua E, Aeschlimann A. The prevalence and incidence of clinical and asymptomatic Lyme borreliosis in a population at risk. *J. Infect. Dis.* 163(2), 305–310 (1991).

45 Gustafson R, Svenungsson B, Gardulf A, Stiernstedt G, Forsgren M. Prevalence of tick-borne encephalitis and Lyme borreliosis in a defined Swedish population. *Scand. J. Infect. Dis.* 22(3), 297–306 (1990).

46 Steere AC, Taylor E, Wilson ML, Levine JF, Spielman A. Longitudinal assessment of the clinical and epidemiological features of Lyme disease in a defined population. *J. Infect. Dis.* 154(2), 295–300 (1986).

47 Seidel MF, Domene AB, Vetter H. Differential diagnoses of suspected Lyme borreliosis or post-Lyme-disease syndrome. *Eur. J. Clin. Microbiol. Infect. Dis.* 26(9), 611–617 (2007).

48 Savely V. Lyme disease: a diagnostic dilemma. *Nurse Pract.* 35(7), 44–50 (2010).

49 Stricker RB, Johnson L. 'Rare' infections mimicking multiple sclerosis: Consider Lyme disease. *Clin. Neurol. Neurosurg.* 113(3), 259–60 (2010).

50 Fritzsche M. Chronic Lyme borreliosis at the root of multiple sclerosis – is a cure with antibiotics attainable? *Med. Hypotheses* 64(3), 438–448 (2005).

51 Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease – United States, 1992–2006. *MMWR Surveill. Summ.* 57(10), 1–9 (2008).

52 Rosati G. The prevalence of multiple sclerosis in the world: an update. *Neurol. Sci.* 22(2), 117–139 (2001).

53 Coyle PK. *Borrelia burgdorferi* antibodies in multiple sclerosis patients. *Neurology* 39(6), 760–761 (1989).

54 Coyle PK, Krupp LB, Doscher C. Significance of reactive Lyme serology in multiple sclerosis. *Ann. Neurol.* 34(5), 745–747 (1993).

55 Halperin JJ, Volkman DJ, Wu P. Central nervous system abnormalities in Lyme neuroborreliosis. *Neurology* 41(10), 1571–1582 (1991).

56 Barsky AJ, Borus JF. Functional somatic syndromes. *Ann. Intern. Med.* 130(11), 910–921 (1999).

57 Hatcher S, Arroll B. Assessment and management of medically unexplained symptoms. *BMJ* 336(7653), 1124–1128 (2008).

58 Smith RC, Dwamena FC. Classification and diagnosis of patients with medically unexplained symptoms. *J. Gen. Intern. Med.* 22(5), 685–691 (2007).

59 Dinerman H, Steere AC. Lyme disease associated with fibromyalgia. *Ann. Intern. Med.* 117(4), 281–285 (1992).

60 Hickie I, Davenport T, Wakefield D *et al.* Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. *BMJ* 333(7568), 575 (2006).

61 Kalish RA, Kaplan RF, Taylor E, Jones-Woodward L, Workman K, Steere AC. Evaluation of study patients with Lyme disease, 10–20-year follow-up. *J. Infect. Dis.* 183(3), 453–460 (2001).

62 Shadick NA, Phillips CB, Sangha O *et al.* Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. *Ann. Intern. Med.* 131(12), 919–926 (1999).

63 Ravdin LD, Hilton E, Primeau M, Clements C, Barr WB. Memory functioning in Lyme borreliosis. *J. Clin. Psychiatry* 57(7), 282–286 (1996).

64 Kaplan RF, Jones-Woodward L. Lyme encephalopathy: a neuropsychological perspective. *Semin. Neurol.* 17(1), 31–37 (1997).

65 Seltzer EG, Shapiro ED, Gerber MA. Long-term outcomes of lyme disease. *JAMA* 283(23), 3068–3069 (2000).

66 Buchwald D, Umali P, Umali J, Kith P, Pearlman T, Komaroff AL. Chronic fatigue and the chronic fatigue syndrome: prevalence in a Pacific Northwest health care system. *Ann. Intern. Med.* 123(2), 81–88 (1995).

67 Chen MK. The epidemiology of self-perceived fatigue among adults. *Prev. Med.* 15(1), 74–81 (1986).

68 Luo N, Johnson JA, Shaw JW, Feeny D, Coons SJ. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. *Med. Care* 43(11), 1078–1086 (2005).

69 Croft P, Rigby AS, Boswell R, Schollum J, Silman A. The prevalence of chronic widespread pain in the general population. *J. Rheumatol.* 20(4), 710–713 (1993).

70 Cerar D, Cerar T, Ruzic-Sabljic E, Wormser GP, Strle F. Subjective symptoms after treatment of early Lyme disease. *Am. J. Med.* 123(1), 79–86 (2010).

71 Barsic B, Maretic T, Majerus L, Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. *Infection* 28(3), 153–156 (2000).

72 Dattwyler RJ, Luft BJ, Kunkel MJ *et al.* Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. *N. Engl. J. Med.* 337(5), 289–294 (1997).

73 Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. *N. Engl. J. Med.* 335(17), 1270–1274 (1996).

74   Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. *Ann. Intern. Med.* 117(4), 273–280 (1992).

75   Nowakowski J, Nadelman RB, Sell R *et al.* Long-term follow-up of patients with culture-confirmed Lyme disease. *Am. J. Med.* 115(2), 91–96 (2003).

76   Smith RP, Schoen RT, Rahn DW *et al.* Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. *Ann. Intern. Med.* 136(6), 421–428 (2002).

77   Wormser GP, Ramanathan R, Nowakowski J *et al.* Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. *Ann. Intern. Med.* 138(9), 697–704 (2003).

78   Kowalski TJ, Tata S, Berth W, Mathiason MA, Agger WA. Antibiotic treatment duration and long-term outcomes of patients with early lyme disease from a lyme disease-hyperendemic area. *Clin. Infect. Dis.* 50(4), 512–520 (2010).

79   Pfister HW, Preac-Mursic V, Wilske B, Einhaupl KM. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. *Arch. Neurol.* 46(11), 1190–1194 (1989).

80   Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhaupl KM. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. *J. Infect. Dis.* 163(2), 311–318 (1991).

81   Mullegger RR, Millner MM, Stanek G, Spork KD. Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children – a prospective study. *Infection* 19(4), 279–283 (1991).

82   Borg R, Dotevall L, Hagberg L *et al.* Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. *Scand. J. Infect. Dis.* 37(6–7), 449–454 (2005).

83   Dotevall L, Hagberg L. Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. *Clin. Infect. Dis.* 28(3), 569–574 (1999).

84   Karkkonen K, Stiernstedt SH, Karlsson M. Follow-up of patients treated with oral doxycycline for Lyme neuroborreliosis. *Scand. J. Infect. Dis.* 33(4), 259–262 (2001).

85   Kohlhepp W, Oschmann P, Mertens HG. Treatment of Lyme borreliosis. Randomized comparison of doxycycline and penicillin G. *J. Neurol.* 236(8), 464–469 (1989).

86   Thorstrand C, Belfrage E, Bennet R, Malmborg P, Eriksson M. Successful treatment of neuroborreliosis with ten day regimens. *Pediatr. Infect. Dis. J.* 21(12), 1142–1145 (2002).

87   Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. *Neurology* 44(7), 1203–1207 (1994).

88   Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. *Arthritis Rheum.* 54(10), 3079–3086 (2006).

89   El Moussaoui R, Opmeer BC, de Borgie CA *et al.* Long term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia. *Chest* 130(4), 1165–1172 (2006).

90   Stricker RB, Johnson L. The Lyme disease chronicles, continued. Chronic Lyme disease: in defense of the patient enterprise. *FASEB J.* 24(12), 4632–4633; author reply 4633–4634 (2010).

91   Stricker RB, Johnson L. Lyme wars: let's tackle the testing. *BMJ* 335(7628), 1008 (2007).

92   Stricker RB, Burrascano J, Winger E. Longterm decrease in the CD57 lymphocyte subset in a patient with chronic Lyme disease. *Ann. Agric. Environ. Med.* 9(1), 111–113 (2002).

93   Stricker RB, Winger EE. Decreased CD57 lymphocyte subset in patients with chronic Lyme disease. *Immunol. Lett.* 76(1), 43–48 (2001).

94   Phillips SE, Mattman LH, Hulinska D, Moayad H. A proposal for the reliable culture of *Borrelia burgdorferi* from patients with chronic Lyme disease, even from those previously aggressively treated. *Infection* 26(6), 364–367 (1998).

95   Bayer ME, Zhang L, Bayer MH. *Borrelia burgdorferi* DNA in the urine of treated patients with chronic Lyme disease symptoms. A PCR study of 97 cases. *Infection* 24(5), 347–353 (1996).

96   Marques A, Brown MR, Fleisher TA. Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls. *Clin. Vaccine Immunol.* 16(8), 1249–1250 (2009).

97   Rauter C, Mueller M, Diterich I *et al.* Critical evaluation of urine-based PCR assay for diagnosis of Lyme borreliosis. *Clin. Diagn. Lab. Immunol.* 12(8), 910–917 (2005).

98   Marques AR, Stock F, Gill V. Evaluation of a new culture medium for *Borrelia burgdorferi*. *J. Clin. Microbiol.* 38(11), 4239–4241 (2000).

99   Tilton RC, Barden D, Sand M. Culture *Borrelia burgdorferi*. *J. Clin. Microbiol.* 39(7), 2747 (2001).

100   Strle F, Maraspin V, Lotric-Furlan S, Ruzic-Sabljic E, Cimperman J. Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans. *Infection* 24(1), 64–68 (1996).

101   Strle F, Preac-Mursic V, Cimperman J, Ruzic E, Maraspin V, Jereb M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. *Infection* 21(2), 83–88 (1993).

102   Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of *Borrelia burgdorferi* DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. *N. Engl. J. Med.* 330(4), 229–234 (1994).

103   Oksi J, Marjamaki M, Nikoskelainen J, Viljanen MK. *Borrelia burgdorferi* detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. *Ann. Med.* 31(3), 225–232 (1999).

104   Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW. Persistence of *Borrelia burgdorferi* following antibiotic treatment in mice. *Antimicrob. Agents Chemother.* 52(5), 1728–1736 (2008).

105   Alban PS, Johnson PW, Nelson DR. Serum-starvation-induced changes in protein synthesis and morphology of *Borrelia burgdorferi*. *Microbiology* 146 (Pt 1), 119–127 (2000).

106   Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on morphology of *Borrelia burgdorferi*. *Antimicrob. Agents Chemother.* 39(5), 1127–1133 (1995).

107   Miklossy J, Kasas S, Zurn AD, McCall S, Yu S, McGeer PL. Persisting atypical and cystic forms of *Borrelia burgdorferi* and local inflammation in Lyme neuroborreliosis. *J. Neuroinflammation* 5, 40 (2008).

108   Brorson O, Brorson SH. *In vitro* conversion of *Borrelia burgdorferi* to cystic forms in spinal fluid, and transformation to mobile spirochetes by incubation in BSK-H medium. *Infection* 26(3), 144–150 (1998).

109 MacDonald AB. Plaques of Alzheimer's disease originate from cysts of *Borrelia burgdorferi*, the Lyme disease spirochete. *Med. Hypotheses* 67(3), 592–600 (2006).

110 Kowalski TJ, Tata S, Berth W, Mathiason MA, Agger WA. Antibiotic treatment duration and long-term outcomes of patients with early lyme disease from a lyme disease-hyperendemic area. *Clin. Infect. Dis.* 50(4), 512–520 (2010).

111 Dattwyler RJ, Wormser GP, Rush TJ *et al.* A comparison of two treatment regimens of ceftriaxone in late Lyme disease. *Wien. Klin. Wochenschr.* 117(11–12), 393–397 (2005).

112 Oksi J, Nikoskelainen J, Hiekkanen H *et al.* Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study. *Eur. J. Clin. Microbiol. Infect. Dis.* 26(8), 571–581 (2007).

113 Steere AC, Hutchinson GJ, Rahn DW *et al.* Treatment of the early manifestations of Lyme disease. *Ann. Intern. Med.* 99(1), 22–26 (1983).

114 Steere AC, Malawista SE, Newman JH, Spieler PN, Bartenhagen NH. Antibiotic therapy in Lyme disease. *Ann. Intern. Med.* 93(1), 1–8 (1980).

115 Weber K, Preac-Mursic V, Wilske B, Thurmayr R, Neubert U, Scherwitz C. A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis. *Infection* 18(2), 91–96 (1990).

116 Asch ES, Bujak DI, Weiss M, Peterson MG, Weinstein A. Lyme disease: an infectious and postinfectious syndrome. *J. Rheumatol.* 21(3), 454–461 (1994).

117 Arashima Y, Kato K, Komiya T *et al.* Improvement of chronic nonspecific symptoms by long-term minocycline treatment in Japanese patients with Coxiella burnetii infection considered to have post-Q fever fatigue syndrome. *Intern. Med.* 43(1), 49–54 (2004).

118 Caperton EM, Heim-Duthoy KL, Matzke GR, Peterson PK, Johnson RC. Ceftriaxone therapy of chronic inflammatory arthritis. A double-blind placebo controlled trial. *Arch. Intern. Med.* 150(8), 1677–1682 (1990).

119 Vermeulen RC, Scholte HR. Azithromycin in chronic fatigue syndrome (CFS), an analysis of clinical data. *J. Transl. Med.* 4, 34 (2006).

120 Stricker RB, Green CL, Savely VR, Chamallas SN, Johnson L. Safety of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease. *Minerva Med.* 101(1), 1–7 (2010).

121 Nadelman RB, Arlin Z, Wormser GP. Life-threatening complications of empiric ceftriaxone therapy for 'seronegative Lyme disease'. *South Med. J.* 84(10), 1263–1265 (1991).

122 Holzbauer SM, Kemperman MM, Lynfield R. Death due to community-associated *Clostridium difficile* in a woman receiving prolonged antibiotic therapy for suspected lyme disease. *Clin. Infect. Dis.* 51(3), 369–370 (2010).

123 Patel R, Grogg KL, Edwards WD, Wright AJ, Schwenk NM. Death from inappropriate therapy for Lyme disease. *Clin. Infect. Dis.* 31(4), 1107–1109 (2000).

124 Weissenbacher S, Ring J, Hofmann H. Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study. *Dermatology* 211(2), 123–127 (2005).

125 Stanek G, Reiter M. The expanding Lyme Borrelia complex – clinical significance of genomic species? *Clin. Microbiol. Infect.* 17(4), 487–493 (2011).

Websites

201 European Union Concerted Action on Lyme Borreliosis (2010) http://meduni09.edis.at/eucalb/cms/index.php?lang=en.

202 Persistent Lyme Empiric Antibiotic Study Europe (PLEASE) http://clinicaltrials.gov/ct2/show/NCT01207739

203 Searching for Persistence of Infection in Lyme Disease http://clinicaltrials.gov/ct2/show/NCT01143558